Cost-effectiveness of pharmacotherapy to reduce obesity

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Veerman, J Lennert ^a   Barendregt, Jan J ^a   Forster, Megan ^a   Vos, Theo ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; CYCLOBUTANE DERIVATIVE; LACTONE;

ARTICLE; AUSTRALIA; BODY WEIGHT; BREAST CANCER; COLON CANCER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; ENDOMETRIUM CANCER; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY CANCER; MORTALITY; OBESITY; OSTEOARTHRITIS; PHARMACEUTICAL CARE; STROKE; WEIGHT GAIN; WEIGHT REDUCTION; COST BENEFIT ANALYSIS; ECONOMICS; TREATMENT FAILURE;

ANTI-OBESITY AGENTS; AUSTRALIA; COST-BENEFIT ANALYSIS; CYCLOBUTANES; DRUG COSTS; HUMANS; LACTONES; OBESITY; TREATMENT FAILURE;

EID: 80055045997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026051     Document Type: Article

References (59)

1. Flegal K, Graubard BI, Williamson DF, Gail MH, (2005) Excess Deaths Associated with Underweight, Overweight and Obesity. JAMA 293: 1864-1867.
2. Gronniger JT, (2006) A Semiparametric Analysis of the Relationship of Body Mass Index to Mortality. American Journal of Public Health 96: 173-178.
3. Peeters AB, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L, (2003) "Obesity in Adulthood and its Consequences for Life Expectancy: A Life Table Analysis.". Ann Intern Medicine 38: 24-32.
4. James WP, Jackson-Leach R, Ni Mhurchu C, Kalamara E, Shayeghi M, et al. (2004) Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks Geneva World Health Organization pp. 497-596.
5. Begg S, Vos T, Barker B, Stevenson C, Stanley L, et al. (2007) The Burden of Disease and Injury in Australia Canberra AIHW.
6. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, et al. (2007) Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 107: 1755-1767.
7. Wing RR, (1999) Physical activity in the treatment of the adulthood overweight and obesity: current evidence and research issues. Med Sci Sports Exerc 31: S547-552.
8. Rucker D, Padwal R, Li SK, Curioni C, Lau DC, (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Bmj 335: 1194-1199.
9. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugarman HJ, et al. (2005) Meta-Analysis: Surgical Treatment of Obesity. Annals of Internal Medicine 142: 547-W-118.
10. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, et al. (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142: 532-546.
11. Pharmaceutical Benefits Advisory Committee (2008) Public Summary Document Sibutramine hydrochloride Canberra Department of Health and Aging.
12. Therapeutic Goods Administration DoHaA, Government of Australia (2010) Sibutramine (Reductil)- withdrawal in Australia Canberra TGA.
13. Department of Health and Ageing (2009) Pharmaceutical Benefits Scheme. DHA. Available: www.pbs.gov.au Accessed 2009 Dec 23.
14. Gold MR, Stevenson D, Fryback DG, (2002) HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health 23: 115-134.
15. Murray CJ, Lopez AD, (1994) Quantifying disability: data, methods and results. Bull World Health Organ 72: 481-494.
16. Neovius M, Narbro K, (2008) Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Int J Obes (Lond) 32: 1752-1763.
17. Padwal R, Li SK, Lau DC, (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27: 1437-1446.
18. Carter R, Vos T, Moody M, Haby MM, Magnus A, et al. (2008) Priority setting in health: origins, description and application of the Australian Assessing the Cost-Effectiveness of Prevention initiative. Expert Reviews Pharmacoeconomic Outcomes Research 8: 593-617.
19. Forster M, Veerman JL, Barendregt JJ, Vos T, (2011) Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. Int J Obes (Lond).
20. Sacks G, Veerman JL, Moodie M, Swinburn B, (2010) 'Traffic-light' nutrition labelling and 'junk-food' tax: a modelled comparison of cost-effectiveness for obesity prevention. Int J Obes (Lond):Epub ahead of print 2010/2011/2017.
21. Cobiac LJ, Vos T, Barendregt JJ, (2009) Cost-effectiveness of interventions to promote physical activity: a modelling study. PLoS Med 6: e1000110.
22. Cobiac LJ, Vos T, Veerman JL, (2010) Cost-Effectiveness of Interventions to Promote Fruit and Vegetable Consumption. PLoS ONE 5: e14148.
23. Barendregt JJ, Van Oortmarssen GJ, Van Hout BA, Van Den Bosch JM, Bonneux L, (1998) Coping with multiple morbidity in a life table. Math Popul Stud 7: 29-49, 109.
24. Forster M, Veerman JL, Barendregt JJ, Vos ET, (2011) Cost-Effectiveness of Diet and Exercise Interventions to Reduce Overweight and Obesity. Int J Obes In press.
25. Cameron AJ, Welborn TA, Zimmet PZ, Dunstan DW, Owen N, et al. (2003) Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 178: 427-432.
26. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119-2125.
27. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ, (2003) A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 1: 4.
28. Haby MM, Markwick A, Peeters A, Shaw J, Vos T, (2011) Future predictions of body mass index and overweight prevalence in Australia, 2005-2025. Health Promot Int.
29. Barendregt JJ, Veerman JL, (2009) Categorical versus continuous risk factors, and the calculation of potential impact fractions. J Epidemiol Community Health.
30. Ni Mhurchu C, Parag V, Nakamura M, Patel A, Rodgers A, et al. (2006) Body mass index and risk of diabetes mellitus in the Asia-Pacific region. Asia Pac J Clin Nutr 15: 127-133.
31. Jacobs P, Fassbender K, (1998) The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care 14: 799-808.
32. Garber AM, Phelps CE, (2008) Future costs and the future of cost-effectiveness analysis. J Health Econ 27: 819-821.
33. Meltzer D, (2008) Response to "Future costs and the future of cost-effectiveness analysis". J Health Econ 27: 822-825.
34. van Baal PHM, Polder JJ, de Wit GA, Hoogenveen RT, Feenstra TL, et al. (2008) Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure. PLoS Med 5: e29.
35. AIHW (2008) Health Expenditure Australia Canberra Australian Institute of Health and Welfare.
36. ABS (2003) ABS Consumer Price Index Canberra Australian Bureau of Statistics.
37. Ezzati M, Lopez AD, Rogers A, Murray CJL, (2003) Comparative Quantification of Health Risks Geneva World Health Organisation.
38. Lipscomb J, (1989) Time preference for health in cost-effectiveness analysis. Medical Care 27: S233-252.
39. George B, Harris A, Mitchell A, (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics 19: 1103-1109.
40. van Baal PH, van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM, (2008) Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 11: 1033-1040.
41. Anderson JW, Konz EC, Frederich RC, Wood CL, (2001) Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579-584.
42. Foxcroft DR, (2005) Orlistat for the treatment of obesity: cost utility model. Obes Rev 6: 323-328.
43. Hertzman P, (2005) The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden: a treatment responder approach. Pharmacoeconomics 23: 1007-1020.
44. Lacey LA, Wolf A, O'Shea D, Erny S, Ruof J, (2005) Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond) 29: 975-982.
45. Ruof J, Golay A, Berne C, Collin C, Lentz J, et al. (2005) Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond) 29: 517-523.
46. Hampp C, Hartzema AG, Kauf TL, (2008) Cost-utility analysis of rimonabant in the treatment of obesity. Value Health 11: 389-399.
47. Hakim Z, Wolf A, Garrison LP, (2002) Estimating the Effect of Changes in Body Mass Index on Health State Preferences. Pharmacoeconomics 20: 393-404.
48. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, et al. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363: 905-917.
49. Curfman GD, Morrissey S, Drazen JM, (2010) Sibutramine-another flawed diet pill. N Engl J Med 363: 972-974.
50. Dansinger ML, Tatsioni A, Wong JB, Mei C, Balk EM, (2007) Meta-analysis: The Effect of Dietary Counseling for Weight Loss. Annals of Internal Medicine 147: 41-W47.
51. Beilby J, Furler J, (2005) General practitioner services in Australia. general practice in australia: 2004 Canberra Commonwealth of Australia.
52. Padwal R, Kezouh A, Levine M, Etminan M, (2007) Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 31: 1567-1570.
53. Carter R, Rankin B, (2006) Economic assessment of the NHFA proposal for a national CHD initiative in general practice. Report submitted to the National Heart Foundation of Australia and its CHD-GP Working Group. Program Evaluation Unit, School of Population Health, The University of Melbourne.
54. ABS (2003) Labour Force Australia 2003 Canberra Australian Bureau of Statistics.
55. ABS (2003) Average Weekly Earnings Canberra Australian Bureau of Statistics.
56. Rankin S, Hughes-Anderson W, House J, Aitken J, Heath D, et al. (2002) Rural residents' utilisation of health and visiting specialist health services. Rural and Remote Health 2: 119.
57. Bamford E, Dunne L, Taylor D, Symon B, Hugo G, et al. (1999) Accessibility to general practitioners in rural South Australia. A case study using geographic information system technology. Medical Journal of Australia 171: 614-616.
58. Organisation for Economic Cooperation and Development (2006) Purchasing Power Parities (PPPs) for OECD Countries 1980-2006.
59. Stinnett AA, Paltiel AD, (1997) Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 17: 483-489.